Document/ExhibitDescriptionPagesSize 1: 8-K Current Report HTML 24K
2: EX-3.1 Articles of Incorporation/Organization or Bylaws HTML 67K
3: EX-3.2 Articles of Incorporation/Organization or Bylaws HTML 120K
8: R1 Document And Entity Information HTML 48K
11: XML IDEA XML File -- Filing Summary XML 12K
9: XML XBRL Instance -- isr20230215b_8k_htm XML 13K
10: EXCEL IDEA Workbook of Financial Reports XLSX 8K
5: EX-101.DEF XBRL Definitions -- isr-20230214_def XML 38K
6: EX-101.LAB XBRL Labels -- isr-20230214_lab XML 49K
7: EX-101.PRE XBRL Presentations -- isr-20230214_pre XML 38K
4: EX-101.SCH XBRL Schema -- isr-20230214 XSD 15K
12: JSON XBRL Instance as JSON Data -- MetaLinks 13± 20K
13: ZIP XBRL Zipped Folder -- 0001437749-23-003634-xbrl Zip 54K
i350 Hills Street, Suite 106, iRichland, iWashingtoni99354
(Address of Principal Executive Offices) (Zip Code)
(i509) i375-1202
(Registrant’s telephone number, including area code)
iIsoray, Inc.
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
i☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
iCommon Stock, $0.001 par value
iISR
iNYSE American
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company i☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On February 14, 2023, Isoray, Inc. (the “Company”) changed its corporate name to Perspective Therapeutics, Inc., pursuant to an Amended and Restated Certificate of Incorporation filed with the Delaware Secretary of State on February 14, 2023 (the “Name Change”). Pursuant to Delaware law, a stockholder vote was not necessary to effectuate the Name Change and it does not effect the rights of the Company’s stockholders. The Company also amended and restated its Bylaws on
February 14, 2023, to reflect the Name Change.
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
